Vernalis CEO insists he's hunting for new drug deals

The CEO of the UK's Vernalis isn't letting a recent clinical trial setback distract him from growing the company's pipeline. Chief Executive Ian Garland was out this morning talking up new plans to in-license experimental drugs or acquire companies with interesting development programs underway in cancer and the central nervous system.

"We look to further expand our pipeline through in-licensing and acquisition," Garland says. "Most likely these acquisitions will be in our areas of focus of oncology and CNS (central nervous system). In-licensing will most likely be preclinical through early human (testing) stage and acquisitions are likely to have unpartnered clinical-stage programs."

Vernalis' shares took a hit last month after the UK developer announced that one of its experimental drugs failed a Phase IIb clinical trial for diabetes-related neuropathic pain. But Vernalis has always managed to stay afloat in turbulent times. Once known as British Biotech, the developer had a two billion pound market cap at one point in the '90s. The company ended its last fiscal year with about $40 million in cash.

- here's the story from Reuters

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.